Author(s): Finn GP, Bozek T, Souhami RL, Slevin ML, Thomas DG, Finn GP, Bozek T, Souhami RL, Slevin ML, Thomas DG
Abstract Share this page
Abstract Twenty-four patients with relapsed primary intracranial tumors were treated with high-dose etoposide (600-1000 mg/m2). All patients had received previous radiotherapy and 15 had had previous chemotherapy. The treatment was well-tolerated, with little toxicity. Only one patient showed a partial response, which was maintained for 78 weeks. Four patients had stable disease, for a median of 15 weeks. Etoposide failed to show useful activity in relapsed brain tumors.
This article was published in Cancer Treat Rep
and referenced in Journal of Cancer Science & Therapy